

	<p>Andrew Owen PhD FRSB FBPhS</p>		
<p>Organisation</p>	<p>University of Liverpool</p>		
	<p>Andrew Owen is a Professor in the Department of Molecular and Clinical Pharmacology at the University of Liverpool, UK. He is also affiliated to the MRC Centre for Drug Safety Science and the Wolfson Centre for Personalised Medicine. He is Chair of the British Society for Nanomedicine, a fellow of the Royal Society of Biology, a fellow of the British Pharmacological Society and a member of the steering committee for the Academy of Pharmaceutical Sciences Nanomedicines Focus Group. His clinical and basic research focuses on understanding the mechanisms that underpin inter-patient variability in pharmacokinetics and pharmacodynamics for drugs used in the management of infectious diseases, predominantly HIV infection. In recent years a major emphasis has been to employ knowledge of these mechanisms to accelerate the translation of nanomedicine candidates to clinical applications. Work is supported by grants from the US Agency for International Development, US National Institutes for Health, the UK Medical Research Council, the European Commission, the UK Engineering and Physical Sciences Research Council, the British Society for Antimicrobial Chemotherapy and the Clinton Health Access Initiative. Professor Owen has published over 140 original research papers, review manuscripts and book chapters. He is co-inventor of patents relating to the application of nanotechnology to drug delivery and a co-founder of Tandem Nano Ltd. He is also an Editor in Chief for the <i>Journal of Interdisciplinary Nanomedicine</i> and a member of the Editorial Board for <i>Nanomedicine; Nanotechnology, Biology and Medicine</i>.</p>		
<p>Role in the EU-NCL</p>	<p>Andrew is member of the Executive Board (ExBo), and leads the workpackage "JRA2 Correlation Analysis of TNA results".</p>		